The Microbiome Business & Science Briefing
MicrobimeTimes
Reporting on The Latest Microbiome Business & Scientific Developments
TRENDING
From Discovery to Disease Prevention: How the Biose–Siolta Partnership is Advancing a New Generation of Live Biotherapeutics• A pioneering gut bacterium passes Europe’s food-safety review under the EU Novel Food Regulation• Stanford’s AI Designed Bacteriophages: Ushering in the Next Phase in IP Strategy for Phage Companies?• Breathing Engineered Bacteria: A New Approach to Treating Lung Disease• Vedanta Biosciences Secures $60 Million in Funding Ahead of Pivotal Phase 3 Data• Gut fungi may hold the key to treating Asthma worldwide•

Category: Clinical & Manufacturing

Synlogic Presents New Preclinical Data from Synthetic Biotic™ Medicine, SYNB1020, Highlighting Beneficial Activity in Animal Model of Liver Disease
Basic & Discovery Research

Synlogic Presents New Preclinical Data from Synthetic Biotic™ Medicine, SYNB1020, Highlighting Beneficial Activity in Animal Model of Liver Disease

JUN 5, 2018
Realm Therapeutics Completes Enrollment in Phase 2 Study of PR022 for Atopic Dermatitis
Clinical & Manufacturing

Realm Therapeutics Completes Enrollment in Phase 2 Study of PR022 for Atopic Dermatitis

MAY 25, 2018
Chr. Hansen reaches major milestone in innovation pipeline
Clinical & Manufacturing

Chr. Hansen reaches major milestone in innovation pipeline

MAY 16, 2018
Jennewein Biotechnologie: First Clinical Trial of a Blend of Human Milk Oligosaccharides Emulating the Human Profile of Infant Formula
Clinical & Manufacturing

Jennewein Biotechnologie: First Clinical Trial of a Blend of Human Milk Oligosaccharides Emulating the Human Profile of Infant Formula

MAY 6, 2018
AOBiome Therapeutics Expands Clinical-Stage Pipeline, Initiates Phase 2 Clinical Trial for Episodic Migraine
Clinical & Manufacturing

AOBiome Therapeutics Expands Clinical-Stage Pipeline, Initiates Phase 2 Clinical Trial for Episodic Migraine

APR 23, 2018
Second Genome Presents Clinical and Preclinical Data Supporting Development of Its P2X7 Inhibitor, SGM-1019, in NASH at the EASL International Liver Congress 2018
Basic & Discovery Research

Second Genome Presents Clinical and Preclinical Data Supporting Development of Its P2X7 Inhibitor, SGM-1019, in NASH at the EASL International Liver Congress 2018

APR 9, 2018
AOBiome Therapeutics Reports Positive Clinical Safety Results for First-in-Class Microbiome-Targeted Therapy for Intranasal Delivery
Clinical & Manufacturing

AOBiome Therapeutics Reports Positive Clinical Safety Results for First-in-Class Microbiome-Targeted Therapy for Intranasal Delivery

MAR 21, 2018